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Abstract
Aims To examine the relationship between hormones involved in bone remodeling and glucose metabolism alterations in 
prediabetes.
Methods Individuals (n = 43) with NGT (BMI = 31.1 ± 1.1 kg/m2) and individuals (n = 79) with impaired glucose regula-
tion (IGR) (BMI = 31.9 ± 1.2 kg/m2) including subjects with IFG, IGT, and IFG-IGT underwent OGTT and DXA. Osteo-
pontin (OPN), osteocalcin (OCN), osteoprotegerin (OPG), and PTH levels were measured at fasting. Beta-cell function was 
calculated using C-peptide deconvolution. Dynamic indexes of insulin sensitivity were calculated from OGTT. A subgroup 
underwent to a euglycemic hyperinsulinemic clamp with 3-3H-glucose to estimate the endogenous glucose production (EGP) 
and insulin-mediated body glucose disposal (TGD/SSPI).
Results OPN was higher in IGR compared to NGT (5.3 ± 0.5 vs. 3.3 ± 0.2 μg/mL; p = 0.008) and in isolated IGT compared 
to IFG and IFG-IGT (6.3 ± 0.5 vs. 4.5 ± 0.3 and 5.4 ± 0.5 μg/mL; p = 0.02). OCN was similar in IFG and NGT but lower in 
IGT and IFG-IGT compared to NGT (7.2 ± 0.3 and 5.4 ± 0.2 vs. 8.3 ± 0.3 ng/mL; p < 0.01). OPN was positively correlated 
with HbA1c, fasting and 2 h plasma glucose and PTH. OCN was negatively correlated with body fat, 2 h plasma glucose, 
insulin and positively correlated with Stumvoll index. OPG correlated with TGD/SSPI (r = − 0.29; p < 0.05), EGP, and 
hepatic insulin resistance index in IGR (r = 0.51, r = 0.43; p < 0.01). There was no correlation between PTH and insulin 
sensitivity or Beta-cell function parameters.
Conclusions In prediabetes, hormones known to be involved in bone remodeling may affect glucose metabolism before overt 
T2DM occurs with tissue-specific mechanisms.
Keywords Osteopontin · Osteocalcin · Osteoprotegerin · Leptin · Adiponectin · Prediabetes · Impaired glucose tolerance · 
Impaired fasting glucose · Impaired glucose regulation · Type 2 diabetes mellitus · Glucose metabolism · Euglycemic 
hyperinsulinemic clamp · Whole body insulin sensitivity · Beta-cell function · Human
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IR  Insulin resistance
IGR  Impaired glucose regulation
IGT  Impaired glucose tolerance
IFG  Impaired fasting glucose
OPN  Osteopontin
OCN  Osteocalcin
OPG  Osteoprotegerin
PTH  Parathyroid hormone
Introduction
Type 2 diabetes mellitus (T2DM) is a progressive disease, 
preceded by a preclinical phase of impaired glucose regu-
lation, in the fasting state and/or in the postprandial state 
(IFG, impaired fasting glucose, and IGT, impaired glucose 
tolerance) [1]. A number of alterations involving different 
tissues have been found to contribute to the development 
and progression of hyperglycemia, and more relevantly, the 
progressive alterations of insulin, glucagon, and somatosta-
tin production and secretion from the endocrine pancreas 
and insulin action in skeletal muscle, liver, and adipose 
tissue are the known hallmarks of prediabetes and T2DM 
[2–6]. Besides the increased risk for T2DM, individu-
als with prediabetes may suffer from complications (e.g., 
nephropathy, retinopathy, neuropathy) traditionally consid-
ered to be complications of T2DM [7–9], which emphasize 
the importance of early diagnosis together with a more in-
depth understanding of its pathogenic determinants. Bone 
has recently emerged as a new important organ in the regu-
lation of glucose metabolism, which might cross talk with 
known physiologically relevant organs for glucose metabo-
lism, by releasing hormones and cytokines such as osteoc-
alcin and sclerostin, that are known to be critical regulators 
of bone mass through its remodeling [10, 11]. Osteocalcin 
(OCN) is an osteoblast-specific protein that is secreted in 
large amounts in the bone extracellular matrix. Beyond the 
effects on bone remodeling, OCN regulates Beta-cell prolif-
eration, insulin gene expression, and secretion in both mice 
and humans suggesting a potential role in glucose metabo-
lism and in the pathogenesis of glucose alterations in T2DM 
physiopathology [12, 13].
Also other cytokines, which are secreted by bone cells 
and are involved in bone remodeling, may also participate in 
glucose metabolism regulation in humans, and their altera-
tions might be involved in the pathogenesis of prediabetes 
and T2DM.
Osteopontin (OPN), a multifunctional protein expressed 
in several different cell types including adipocytes, with the 
bone being a major production source, binds to integrins 
and CD44 receptors to recruit macrophages and T cells to 
inflammatory sites. OPN has been shown to be increased 
in T2DM [5], and it is probably implicated in subclinical 
inflammation [5], insulin resistance [14], obesity, and obe-
sity-induced hepatic steatosis. Osteoprotegerin (OPG) is an 
inflammatory cytokine receptor implicated in bone remod-
eling. It is a soluble glycoprotein of the tumor necrosis fac-
tor receptor superfamily, responsible for osteoclastogenesis 
inhibition [15]. OPG is expressed in vivo by vascular smooth 
muscle cells, hepatocytes, and osteoblasts, and it might be an 
important factor to understand the relationship between bone 
mineralization and vascular pathology, i.e., atherosclerotic 
plaques calcification. Clinical studies have implicated OPG 
as a risk factor for progressive atherosclerotic cardiovascular 
disease [16, 17]. The adipose tissue-derived hormones leptin 
and adiponectin are independently and inversely associated 
with insulin resistance, glucose metabolism, and subclinical 
inflammation. However, they might also be involved in the 
bone–glucose metabolism cross talk because both adiponec-
tin and leptin have a role in modulating bone resorption and 
osteoblasts differentiation and activation [18].
The aim of the present study is to investigate the relation-
ship between bone-derived hormones potentially involved 
in the regulation of glucose metabolism (OPN, OCN, and 
OPG) by evaluating insulin sensitivity and beta-cell function 
in subjects with normal glucose tolerance and prediabetes, 
with OGTT and the euglycemic clamp.
Research design and methods
The study population included 43 healthy normal glucose 
tolerant (NGT) individuals and 79 individuals with impaired 
glucose regulation (IGR). In this population group, we have 
previously studied the relationship between sclerostin and 
glucose homeostasis [11]. All subjects underwent an oral 
glucose (75 g) tolerance test (OGTT), dual-energy X-ray 
absorptiometry (DXA) whole body scan for body composi-
tion and determination of serum osteopontin, total osteoc-
alcin, osteoprotegerin, parathyroid hormone (PTH), leptin, 
and adiponectin levels. A subgroup (n = 18 with NGT and 
n = 30 with IGR) underwent also a euglycemic hyperinsu-
linemic clamp in combination with tritiated glucose infu-
sion, to directly assess whole body glucose uptake (which 
is primarily skeletal muscle glucose uptake) and hepatic 
glucose production in the fasting state and its suppression 
after insulin infusion (Supplementary Fig. 1). The study pro-
tocol was approved by the Institutional Review Board of the 
University of Texas Health Science Center and the South 
Texas Veterans Healthcare System, Audie Murphy Hospital 
at San Antonio, Texas. The study protocol was conducted in 
accordance with the guidelines of the Declaration of Hel-
sinki. Written and oral informed consent was obtained from 
all participants enrolled in the study.
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Study procedures
All metabolic studies were carried out in the morning at the 
Bartter Research Unit of the South Texas Veterans Health-
care System, following a 10–12 h overnight fast.
1. OGTT: A catheter was placed in an antecubital vein, and 
blood samples were collected at − 30, − 15, 0, 30, 60, 
90, and 120 min for determination of plasma glucose 
(PG), C-peptide, insulin, glucagon, and FFA concentra-
tions.
2. Serum osteopontin, total osteocalcin, osteoprotegerin, 
PTH, leptin, and adiponectin levels were measured at 
fasting.
3. Hyperinsulinemic euglycemic clamp was performed as 
previously described [11] (Supplementary Fig. 2).
4. DXA: DXA whole body scan was performed to deter-
mine fat and lean body mass and whole body minus head 
bone mineral density (Hologic, Waltham, MA, USA).
Calculations
Beta-cell function was assessed from the OGTT using a 
model describing the relationship between insulin secretion 
(ISR, expressed in pmol.min−1 m−2) and glucose concentra-
tion as the sum of two components. The Beta-cell glucose 
sensitivity, the rate sensitivity, and the potentiation factor 
were estimated from glucose and C-peptide concentrations 
(using C-peptide deconvolution) as previously described [19, 
20]. Under steady-state post-absorptive conditions, the rate 
of endogenous glucose appearance (Ra) was calculated as 
the 3-3H-glucose infusion rate (DPM/min) divided by the 
steady-state plasma 3-3H-glucose specific activity (DPM/
mg). During the euglycemic insulin clamp, the rate of 
glucose appearance (Ra) was calculated with the Steele’s 
equation, using a distribution volume of 250 mL/kg [21]. 
Endogenous (primarily reflecting hepatic) glucose produc-
tion (EGP) was calculated by subtracting the exogenous 
glucose infusion rate from Ra. The rate of insulin-mediated 
total body glucose disposal (TGD/SSPI), hepatic insulin 
resistance index, and adipose tissue insulin resistance index 
(ATIRI) was calculated as previously described [11].
Biochemical and hormonal analysis
Serum osteopontin, total osteocalcin, osteoprotegerin, PTH, 
adiponectin, and leptin levels were measured using the 
human-specific Milliplex map kit according to the manu-
facturer’s instructions in duplicate (Millipore, St Charles, 
MO, USA). The intra-assay and inter-assay variability was 
< 5%. Plasma glucose levels were measured using the glu-
cose oxidase method (GM9; Analox Instruments, London, 
UK). Plasma insulin and C-peptide levels were measured 
by RIA method (Siemens Medical Solutions Diagnostics, 
Tarrytown, NY). Plasma 3-3H-glucose radioactivity was 
measured in Somogyi serum precipitates.
Table 1  Circulating levels of Osteopontin, Total Osteocalcin, Osteoprotegerin, PTH, Adiponectin and Leptin according to glucose tolerance 
status.
* p < 0.05 versus NGT
£ p < 0.05 versus IFG
& p < 0.05 versus IFG and IGT
Characteristic (mean ± SEM) NGT (n = 43) IGR (n = 79) IFG (n = 27) IGT (n = 18) IFG and IGT (n = 34) p value
Osteopontin (μg/L) 3.3 ± 0.2 5.3 ± 0.5* 4.5 ± 0.3 6.3 ± 0.5£ 5.4 ± 0.5£ < 0.05
Total osteocalcin (ng/mL) 8.3 ± 0.3 7.1 ± 0.4 8.0 ± 0.5 7.2 ± 0.3£ 5.4 ± 0.2£ 0.02
Osteoprotegerin (pg/mL) 458 ± 16 436 ± 18 443 ± 39 455 ± 54 421 ± 20 ns
PTH (pg/mL) 147 ± 8 147 ± 6 137 ± 10 141 ± 12 159 ± 13 ns
Adiponectin (μg/mL) 6362 ± 562 4835 ± 302* 4697 ± 426 4894 ± 606 4915 ± 541£ < 0.05
Leptin (ng/mL) 22.6 ± 2.7* 29.5 ± 2.7* 26.8 ± 3.9 24.8 ± 4.6 34.3 ± 4.1£ < 0.05
Characteristic (mean ± SEM) NGT (n = 18) IGR (n = 30) IFG (n = 12) IGT (n = 4) IFG and IGT (n = 14) p value*
Clamp subgroup
 Osteopontin (μg/L) 2.9 ± 0.4 4.8 ± 0.8* 5.5 ± 1.1 5.7 ± 1.9 3.9 ± 1.3& 0.04
Total osteocalcin (ng/mL) 7.0 ± 0.5 7.0 ± 0.7* 8.5 ± 1.5 7.9 ± 1.3 5.7 ± 0.6£ 0.04
Osteoprotegerin (pg/mL) 480 ± 40 404 ± 18 433 ± 29 345 ± 76 396 ± 22 0.06
PTH (pg/mL) 131 ± 16 129 ± 9 135 ± 14 108 ± 7 129 ± 15 ns
Adiponectin (μg/mL) 6.3 ± 0.9 4.3 ± 0.5* 4.8 ± 0.7 6.5 ± 1.6 3.2 ± 0.5& 0.008
Leptin (ng/mL) 24.6 ± 4.4 28.7 ± 3.7 32.8 ± 7.5 22.6 ± 1.2 27.0 ± 3.8 ns
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Statistical analysis
Values were calculated as mean ± SEM or as median (inter-
quartile range) for variables with a skewed distribution. 
The difference between means in NGT and IGR was com-
pared with two-sided unpaired t test and repeated-measures 
ANOVA, with time and group as factors. In order to further 
explore the association between bone markers and glucose 
metabolism alterations, we also performed a subgroup anal-
ysis on IFG, IGT, and combined IFG/IGT subjects, using 
ANOVA and post hoc analysis. Variables that were not nor-
mally distributed were log-transformed before analysis. A 
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p value of < 0.05 (two-tailed analysis) was considered to 
be statistically significant. Pearson correlation (normal dis-
tribution) and Spearman correlation analyses (non-normal 
distribution) were used to assess the correlations between 
serum bone makers and other continuous parameters, and 
we used partial correlations to correct the possible influ-
ence of age, sex, BMI, body fat. Multivariate analyses were 
performed to evaluate the contribution of bone markers in 
the association with insulin resistance, insulin sensitivity, 
and insulin clearance. Data were analyzed using SPSS 20 
(Statistical Package for Social Sciences, Chicago, IL, USA).
Results
Baseline characteristic of the study population
The characteristics of the whole population studied are 
reported in Supplementary Table 1. The characteristics of 
subgroup subjects studied by the hyperinsulinemic euglyce-
mic clamp are reported in the Supplementary Table 2. The 
two study groups were well matched in age, sex, BMI, fat 
and lean body mass, and bone density.
Bone metabolism markers in NGT and IGR subjects 
at fasting
Osteopontin serum levels were higher in IGR as compared 
to NGT (5.3 ± 0.5 vs. 3.3 ± 0.2 μg/L; p = 0.008) (Table 1). 
However, when subjects were divided according to glucose 
tolerance status, osteopontin tended to be higher in isolated 
IGT and combined IFG-IGT subjects compared to NGT 
subjects being significantly higher in isolated IGT only 
(6.3 ± 0.5 vs. 3.3 ± 0.2 μg/L; p = 0.02). Total osteocalcin 
serum levels did not differ between NGT and IGR but when 
subjects were divided according to glucose tolerance sta-
tus, total osteocalcin serum levels were significantly lower 
in combined IFG-IGT and isolated IGT subjects as com-
pared to IFG and NGT subjects (5.4 ± 0.2 and 7.2 ± 0.3 vs. 
8.0 ± 0.5 and 8.3 ± 0.3, p < 0.01 IFG-IGT vs. NGT and IFG; 
p < 0.01 IGT vs. NGT and IFG, respectively).
Adiponectin was significantly higher in NGT as compared 
to IGR, while leptin was significantly lower in NGT as com-
pared to IGR.
Serum osteoprotegerin levels were not significantly 
higher in NGT compared to IGR, and PTH levels were simi-
lar between NGT and IGR. These levels did not differ across 
glucose tolerance status subgroups. When subjects were fur-
ther divided according to sex or ethnicity, osteopontin, total 
osteocalcin, osteoprotegerin, and PTH levels were similar 
in males and females in both the NGT and IGR groups and 
no differences were found in subgroup analysis (data not 
shown). Adiponectin was higher in NGT as compared to 
IGR, while leptin was lower in NGT as compared to IGR.
Relationships between bone metabolism markers 
and glucose metabolism
Serum osteopontin levels were positively correlated with 
fasting glucose (r = 0.27; p = 0.002) (Fig. 1a), 2-hours 
plasma glucose (r = 0.24; p = 0.004) (Fig. 1b), HbA1c 
(r = 0.31; p < 0.001) (Fig. 1c), and fasting plasma insulin 
(r = 0.17; p = 0.04) (Fig. 1d). Moreover, osteopontin levels 
were negatively correlated with OGIS (r = − 0.22; p = 0.01) 
(Fig. 1e) and TGD/SSPI (r = − 0.28; p = 0.02) (Fig. 1f).
A multiple linear regression modeling was performed 
using 2 h plasma glucose as a dependent variable (Supple-
mentary Table 3). In model 1, independent variables were 
body fat, BMI, age, and HbA1c. In model 2, osteopontin 
was added as independent variable to model 1 to assess the 
association of osteopontin with 2 h plasma glucose. In model 
1, body fat was independently associated with 2 h plasma 
glucose (r2 = 0.166; p = 0.001). In model 2, osteopontin 
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was independently associated with 2 h plasma glucose and 
increased the r2 as compared to model 1 (r2 change: 0.032; 
F change: 4.019; p = 0.04).
Serum total osteocalcin levels were negatively corre-
lated with 2-hours plasma glucose (r = − 0.19; p = 0.04) 
(Fig. 2a), 2-hours plasma insulin (r = − 0.21; p = 0.02) 
(Fig. 2b), and FFA (r = − 0.21; p = 0.02) (Fig. 2c), while no 
significant correlations were found between total osteocalcin 
and HbA1c, fasting plasma glucose and 2-hours plasma glu-
cose. Circulating osteoprotegerin levels were inversely cor-
related with TGD/SSPI (r = − 0.29; p = 0.02 (Fig. 3a) and 
positively correlated with fasting EGP (r = 0.51; p = 0.01) 
(Fig. 3b) and HIRI (r = 0.43; p = 0.01) (Fig. 3c).
A multiple linear regression modeling was performed 
using fasting plasma glucose as dependent variable (Sup-
plementary Table 3). In model 1, independent variables were 
body fat, BMI, age, and HbA1c. In model 2, osteoprotegerin 
was added as independent variable to model 1 to assess the 
association of osteoprotegerin with each dependent variable 
included in the model. In model 1, HbA1c was indepen-
dently associated with fasting plasma glucose (r2 = 0.175; 
p = 0.001). In model 2, osteoprotegerin was independently 
associated with fasting plasma glucose and increased the 
r2 as compared to model 1 (r2 change: 0.057; F change: 
7.551; p = 0.007). Similarly, HbA1c was separately used 
as dependent variable (model 1). As expected, in model 1, 
fasting plasma glucose was independently associated with 
HbA1c (r2 = 0.190). In model 2, osteoprotegerin was inde-
pendently associated with HbA1c and increased the r2 (r2 
change: 0.032; F change: 4.160; p = 0.044).
A multiple linear regression analysis was performed 
using fasting EGP as a dependent variable. In model 1, 
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independent variables were body fat, BMI, fasting plasma 
glucose, fasting plasma insulin, age, and HbA1c. In model 
2, osteoprotegerin was added as independent variable to 
model 1 to assess the contribution of osteoprotegerin to 
the association with fasting EGP. BMI was independent 
predictor of fasting EGP (r2 = 0.534). Consistently, in 
model 2, osteoprotegerin was independently associated 
with fasting EGP and increased the r2 (r2 change: 0.145; 
F change: 5.901; p = 0.025).
PTH levels were not correlated with any of the glucose 
metabolism parameters examined.
There was no significant correlation between osteo-
pontin, osteocalcin, osteoprotegerin, and PTH with beta-
cell function parameters (i.e., fasting and total insulin 
secretory rates, glucose sensitivity, rate sensitivity, and 
potentiation factor) (Supplementary Table 4), ATIRI and 
insulin clearance at baseline and during OGTT (data not 
shown).
Relationship between bone metabolism markers 
and adipocytokines with bone density and body 
composition
Circulating osteopontin levels were positively correlated 
with leptin (r = 0.19; p = 0.03) (Fig. 4a) but not with 
adiponectin (r = 0.07; p = 0.46) (Fig. 4b). Moreover, 
osteopontin was positively correlated with PTH (r = 0.26; 
p = 0.01) and inversely with bone density (r = − 0.22, 
p = 0.03) (Fig. 4c, d).
Total Osteocalcin levels were negatively correlated 
with leptin (r = − 0.24; p = 0.009) (Fig. 5a) and posi-
tively with adiponectin although it was not significant 
(r = 0.18; p = 0.05) (Fig. 5b). Total osteocalcin levels 
were also inversely correlated with body fat (r = − 0.25; 
p  =  0.009) and positively correlated with lean mass 
(r = 0.25; p = 0.009) (Fig. 5c, d).
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Discussion
This study demonstrates that circulating OPN levels 
increase as the glucose tolerance deteriorates in humans. 
This evidence is supported by the inverse and significant 
relationship between OPN levels and plasma glucose 
profiles and insulin sensitivity, suggesting a potential 
combined role in the glucose homeostasis abnormalities 
underlying prediabetes. We and others have shown that 
OPN levels are increased in type 1 and type 2 diabetes 
[5, 22] and in obesity and correlate with insulin resist-
ance and hyperglycemia. Also increased circulating OPN 
is a marker of early coronary arteries calcification in type 
2 diabetes [23] and a strong predictor of incipient dia-
betic nephropathy and all-cause mortality in type 1 dia-
betes [23]. OPN is associated with a subclinical inflam-
matory status, hyperglycemia, and insulin resistance in 
T2DM, and the present results suggest that it may exert 
its pro-inflammatory effect before the onset of T2DM, in 
its preclinical stage, i.e., IGR [5]. Conversely, total OCN 
levels decrease in IGR as compared to NGT in particular 
in subjects with both IFG and IGT. Several studies have 
reported low OCN levels in patients with diabetes and 
metabolic syndrome and the correlations between OCN 
and parameters of glucose metabolism have largely been 
consistent with animal models [23]. Also OCN levels were 
lower in diabetic compared to non-diabetic patients with 
metabolic syndrome [24]. Moreover, OCN levels were 
inversely associated with plasma glucose levels and fat 
mass in type 2 diabetes, and our study confirms the finding 
in prediabetes. Interestingly, we find a positive correlation 
between lean mass and OCN levels implying that OCN 
might be possibly involved in the modulation of skeletal 
muscle trophism, which is also impaired in T2DM. This 
hypothesis is supported by recent evidences that demon-
strated that OCN receptors are expressed in mouse mus-
cle and exogenous OCN administration augments insu-
lin-stimulated skeletal muscle glucose uptake in C2C12 
myotubes favoring the translocation of GLUT4 to the 
plasma membrane and following ex vivo muscle contrac-
tion [25]. Osteocalcin is also directly correlated with adi-
ponectin, another important insulin-sensitizing hormone 
[26]. Moreover, OCN favors FA catabolism in myofibers. 
In animal studies, exogenous OCN increases the cellular 
energy sensor AMPK phosphorylation which promotes FA 
utilization in muscle by increasing the activity of CPT1B, 
a transporter of long-chain FAs into the mitochondria. On 
the other hand, OCN is inversely correlated with leptin and 
body fat mass, suggesting another potential aspect of body 
composition by which OCN might be finally involved in 
the regulation of glucose metabolism [25, 27].
Our results demonstrate that OCN levels are significantly 
and inversely correlated with circulating FFA concentration 
independently of BMI and insulin resistance, suggesting that 
it may it might be involved in the modulation of FFA utili-
zation. On the other hand, non-alcoholic fatty liver disease 
(NAFLD) is strongly associated with insulin resistance [28] 
and a large portion of NAFLD patients have postprandial 
hyperinsulinaemia and abnormal glucose tolerance. As 
steatosis leads to decreased hepatic insulin sensitivity and 
increased gluconeogenesis, it has been hypothesized that 
NAFLD precedes the development of T2DM [29].
Primary NAFLD was a strong risk factor for impaired 
glycemic control at the population level independently 
of a wide range of confounders including insulin, adipo-
cytokines, metabolic syndrome, physical activity, weight 
change during follow-up, and dietary intake. Recent evi-
dences demonstrated that OPG levels were positively asso-
ciated with visceral adipose tissue, HOMA-IR, adipokines 
arterial stiffness, and the number of atherosclerotic sites 
[30]. More interestingly, OPG was also associated with liver 
steatosis markers and liver fat content, suggesting a possible 
role of liver steatosis in the overproduction of OPG in meta-
bolic patients [30]. In our study, high OPG circulating levels 
are associated with higher endogenous glucose production 
(primarily reflecting liver glucose production) and hepatic 
insulin resistance in IRG. These findings support the pos-
sibility that OPG might play a role in glucose homeostasis 
alterations which usually precede overt T2DM. Moreover, 
adipose tissue may have a direct role in metabolic alterations 
underlying prediabetes modulating the bone markers poten-
tially affecting the glucose metabolism. Leptin activates β-2 
adrenergic receptors on osteoblasts through the sympathetic 
nervous system and thereby decreases the differentiation 
and activation of osteoblasts while increasing the activity 
of osteoclasts in bone resorption. Hence, increased leptin is 
detrimental to bone formation while increasing bone resorp-
tion. Conversely, adiponectin stimulates the differentiation 
and mineralization of the osteoblast, while inhibiting osteo-
clast activity and bone resorption [31]. Moreover, several 
evidences demonstrated that both leptin and adiponectin can 
directly affect glucose metabolism [26, 32]. In the present 
study, both OPN and OCN are significantly correlated with 
leptin and adiponectin, suggesting that the modulation of 
glucose metabolism may be also interconnected and medi-
ated by their effects on bone metabolism; therefore, further 
studies are needed to explore the molecular mechanisms 
underlying this cross talk. Moreover, it has been shown that 
excess PTH in subjects with chronic renal failure plays a 
major role in the genesis of the glucose intolerance of uremia 
[33]. Our study has some limitations. The cross-sectional 
design does not allow the study of potential changes in bone 
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markers levels in the natural history of IGR, thus possibly 
providing a stronger link between glucose metabolism alter-
ations and bone markers levels. Calcium and 25(OH) vita-
min D have a role in the regulation of glucose metabolism 
[34–36]; however, calcium and 25(OH) vitamin D status has 
not been evaluated in this study. Future studies should evalu-
ate the relation between bone-derived hormones, including 
sclerostin, osteopontin, osteoclastin, and osteoprotegerin 
with 25(OH) vitamin D, given their role in the regulation of 
glucose metabolism and insulin secretion, in humans. The 
sample size might affect the statistical power, although the 
study groups were well matched for age, sex, BMI, and body 
composition, including bone density. Correlations do not 
prove “cause and effect,” and additional factors may mod-
ulate the relationship between bone markers and glucose 
metabolism. Strengths of our study are the evaluation of 
circulating serum bone markers in subjects with NGT and 
IGR combined with the extensive and detailed evaluation 
of biochemical and clinical parameters of glucose metabo-
lism, derived from OGTT and the gold-standard, euglyce-
mic clamp with glucose tracer to evaluate hepatic glucose 
production. Also the results of this study add evidences on 
support of a complex inter-organ communication since bone 
is increasingly being recognized as an endocrine tissue that 
participates in regulating whole body fuel metabolism and 
glucoregulation. Moreover, it has been shown that bone 
mass represents a remarkable percentage of body weight. 
It should be noted that dual-energy X-ray absorptiometry 
(DXA) is based on the chemical model and does not provide 
a reliable measure of bone mass of an individual, since a 
direct method measuring the bone weight through dissec-
tion may be well-founded. The most important study on this 
topic is the Belgium study that demonstrated that the adipose 
tissue-free weight of bone is around 20% in men and 21% in 
women [37] and these percentages were similar to percent-
ages observed in non-human primates [38].
This and previous studies in humans as well as mechanis-
tic studies in cell and rodent models suggest that bone might 
represent a new important player in the regulation of glucose 
metabolism in aging and type 2 diabetes mellitus [5, 11, 
39–41]. In conclusion, we believe that future studies should 
address the possibility that new drugs might be designed 
to target these novel markers of bone homeostasis as well 
as glucose metabolism in the elderly population, which is 
frail and more prone to type 2 diabetes and osteoporosis and 
related complications [42, 43].
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